Mujkanovic Jasmin, Tanderup Kari, Agerbæk Mads, Bisgaard Ulla, Høyer Søren, Lindegaard Jacob Christian, Fokdal Lars
Department of Oncology.
Department of Urology.
J Contemp Brachytherapy. 2016 Oct;8(5):434-437. doi: 10.5114/jcb.2016.63461. Epub 2016 Nov 7.
Primary urethral cancer (PUC) is a very rare disease. This case report illustrates a successful treatment approach of a 67-year-old woman with a urethral adenocarcinoma selected for an organ preserving treatment with external beam radiotherapy (EBRT) and interstitial brachytherapy (BT) boost, using the GEC-ESTRO target concept originally designed for locally advanced cervical cancer (LACC). Treatment included EBRT with 45 Gy in 25 fractions followed by image guided adaptive interstitial BT (IGABT) with a pulsed-dose-rate (PDR) BT boost with 30 Gy in 50 hourly pulses. The D for CTV was 79.1 Gy in EQD2. At 24 months follow-up, the patient was recurrence free and without treatment related side effects.
原发性尿道癌(PUC)是一种非常罕见的疾病。本病例报告展示了一种成功的治疗方法,该方法用于一名67岁患有尿道腺癌的女性,采用了最初为局部晚期宫颈癌(LACC)设计的GEC-ESTRO靶区概念,选择了外照射放疗(EBRT)和组织间插植近距离放疗(BT)增敏的器官保留治疗。治疗包括25次分割给予45 Gy的EBRT,随后进行图像引导的自适应组织间插植近距离放疗(IGABT),采用脉冲剂量率(PDR)近距离放疗增敏,50个小时脉冲给予30 Gy。CTV的等效均匀剂量(EQD2)为79.1 Gy。随访24个月时,患者无复发且无治疗相关副作用。